Recombinant adenoviral vectors (AdVTNF-a) expressing a tumor necrosis factor (TNF-a) under control of cytomegalovirus (CMV) promoter have been used in cancer gene therapy. To reduce its cytotoxicity, we constructed a recombinant AdV TERT mTNF-a expressing a mutant TNF-a (mTNF-a) with mutations at D142N and A144R under control of human telomerase reverse transcriptase (hTERT) promoter for treatment of well-established ovalbumin (OVA)-expressing murine B16 melanoma (BL6-10 OVA ) (6 mm in diameter). We demonstrated that the mTNF-a with mutations at D142N and A144R has less in vitro cytotoxicity, but maintains its functional effect in the stimulation of T-cell proliferation. The in vitro and in vivo transgene expressions under control of hTERT promoter are highly restricted in tumor cells compared with those under the control of the CMV promoter. AdV TERT mTNF-a gene therapy by intratumoral injection of AdV TERT mTNF-a vector (2 Â 10 9 PFU) expressing the mutant mTNF-a under control of hTERT promoter reduces its in vivo toxicity, eradicates well-established BL6-10 OVA tumors in 4/10 tumor-bearing mice, and induces OVAspecific CD8 þ T-cell-mediated long-term antitumor immunity. Therefore, AdV TERT mTNF-a gene therapy may be very useful in the immunotherapy of cancer.
Introduction
Alpha tumor necrosis factor (TNF-a) was originally discovered as a tumoricidal protein capable of causing hemorrhagic necrosis in transplanted solid tumors in mice. 1 Substantial evidence has now proven that TNF-a is a multifunctional and immunoregulatory cytokine that has antitumor activity, evokes apoptosis, upregulates adhesion molecules and activates immune cells such as macrophages, dendritic cells, neutrophils and T cells. [2] [3] [4] As its antitumor properties have been demonstrated in a variety of in vivo experimental models, [5] [6] [7] TNF-a has attracted attention as a potential antitumor reagent. 8, 9 Unfortunately, the systemic administration of the recombinant TNF-a protein in clinical trails for cancer patients have been limited by the problem of dose-limiting toxicities, because the maximal-tolerated dose of TNF-a in humans is 40-fold less compared with mice on the weight for weight basis. 10 Therefore, severe side-effects are often seen in cancer patients receiving TNF-a treatment. These include septic-like shock syndrome, hypotension, malaise, diarrhea, leukothrombopenia, anorexia, and so on. [8] [9] [10] The p55 TNF-a receptor (TNFR) is primarily responsible for signaling in variety of responses including cytotoxicity 11, 12 and cytokine secretion, 13 whereas the p75 TNFR is responsible for lymphoproliferative signals and activation of T cells. 12, 14, 15 To induce high local concentration of TNF-a while limiting systemic use of a high dose of TNF-a, isolated limb perfusion with TNF-a has been applied with less systemic toxicity. 16, 17 These results prompted a number of studies aimed at decreasing TNF-a toxicity without modifying its antitumor properties, thereby allowing its use not only for regional treatments but also for systemic therapy. The strategies include encapsulation of TNF-a in liposomes, 18 targeted delivery of TNF-a to tumors through its coupling to specific ligands [19] [20] [21] and engineering of mutant TNF-a with less toxicity. 22 To reduce the toxicity derived from the binding of murine TNF-a to its p55 receptor, point mutations at D142N and A144R of TNF-a protein generated by site-directed mutagenesis resulted in the loss of binding of mutant TNF-a to its p55 receptor and reduced in vivo toxicity. 12 An alternative is the direct in vivo gene delivery mediated by adenoviruses (AdVs) expressing TNF-a. It has been reported that intratumoral (i.t.) administration of recombinant adenoviral vectors (AdVTNF-a) resulted in the transgene expression of TNF-a in tumors, detection of serum TNF-a within 1-2 days, 23 and regression of small palpable tumors within 2-3 days in a mouse model, 12, [23] [24] [25] but not well-established experimental tumors, though the tumor growth in these treated mice was much slower. 25 Telomerase is highly active in immortalized cell lines and tumors, but inactive in most somatic cells. 26, 27 It is a specialized DNA polymerase responsible for replication of chromosome ends, or telomeres. The human telomerase reverse transcriptase (hTERT) is a ribonucleoprotein complex responsible for the addition of T 2 AG 3 repeats to the telomere ends of chromosomes. 28, 29 hTERT expression is highly correlated with telomerase activity. 30 Because the hTERT gene is highly active in tumor cells but repressed in normal cells and its expression is regulated at the transcriptional level, the hTERT promoter has been extensively used for tumor-specific expression of transgenes. [31] [32] [33] Therefore, another alternative to reduce the side-effect of transgene TNF-a to normal tissues is to use hTERT promoter to drive transgene TNF-a expression.
In this study, we generated a mutant murine TNF-a (mTNF-a) gene with mutations at D142N and A144R by site-directed mutagenesis and constructed recombinant adenoviral vectors (AdV) AdV TERT LacZ, AdV TERT Luc and AdV TERT mTNF-a expressing LacZ, luciferase and mTNF-a under control of hTERT promoter, respectively. We investigated the in vitro and in vivo restricted transgene expression to tumor cells using AdV TERT LacZ and AdV TERT Luc. We demonstrated that AdV TERT mTNF-a gene therapy eradicated well-established ovalbumin (OVA)-expressing BL6-10 OVA tumors (B6 mm in diameter) in 4/10 tumor-bearing mice and induced an OVAspecific CD8 þ T-cell-mediated long-term antitumor immunity.
Materials and methods

Cell lines, antibodies, cytokines, peptides and animals
The recombinant murine TNF-a was purchased from R&D Systems (Minneapolis, MN). BL6-10 is a murine B16 melanoma cell line with high lung metastasis. 34 The ovalbumin (OVA)-expressing BL6-10 OVA cell line was generated in our laboratory by transfection of BL6-10 cells with transgene OVA and maintained in a Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (FCS) and G418 (0.5 mg ml Site-directed mutagenesis Polymerase chain reaction mutagenesis was used to introduce mutations at D142N and A144R of TNF-a gene in a mammalian expression vector pCI-TNF-a 25 by site-directed mutagenesis. 36 Sequences of mutant TNF-a at D142N and A144R were verified by the dideoxy nucleotide sequencing method.
Construction of recombinant adenoviral vectors
AdVpLpA without transgene expression as well as AdVLacZ, AdVLuc and AdVTNF-a expressing the E. coli b-gal marker gene LacZ, the firefly luciferase and the murine TNF-a under control of cytomegalovirus (CMV) promoter were available in our laboratory. 25 AdV TERT pLpA without transgene expression as well as AdV TERT LacZ, AdV TERT Luc and AdV TERT mTNF-a expressing LacZ, Luc and mutant TNF-a under control of hTERT promoter were constructed by replacing the CMV promoter with the hTERT core promoter using the AdEasy system (Stratagene, La Jolla, CA) by recombinant DNA technology as described earlier. 37 The recombinant adenoviral vectors were then transfected into 293 cells using Lipofectamine (GIBCO, Gaithersburg, MD) according to the manufacturer's protocol. All recombinant adenoviruses were amplified in 293 cells, purified by a series of cesium chloride ultracentrifugation gradients and stored at À80 1C until use. Virus titers were determined by optical absorbance at A260 nm (one A260 nm unit ¼ 10 12 particles per ml) or by plaque assay. Particle/plaque ratios normally fell between 50:1 and 100:1. All of the viral preparations were free of contamination by E1 þ adenovirus and endotoxin.
TNF-a ELISA
To assess the amount of TNF-a secretion in transfected tumor cell culture, we performed an enzyme-linked immunoadsorbent assay (ELISA) using TNF-a ELISA kit purchased from R&D Systems (Minneapolis, MN) according to the manufacturer's protocol.
Functional TNF-a assays BL6-10 OVA tumor cells were also cultured in a mediumcontaining AdVmTNF-a or AdVTNF-a at multiplicity of infection (MOI) of 200 for 2 h. 38 Medium-containing virus were then removed and replaced with the regular medium. Cells were cultured for another 24 h and the culture supernatants containing the secreted TNF-a and mTNF-a were harvested for examination of the functional effect of mTNF-a. In T-cell proliferation assay, CTLL-2 cells were deprived of IL-2 for 24 h in culture and aliquoted into 96-well microtiter plates (5 Â 10 4 cells per well). To one set of wells containing CTLL-2 cells, the recombinant TNF-a at 2.4 pmol l À1 and its 5-fold dilutions were added. To another set of wells, the culture supernatants were added. In cytotoxicity assay, L929 (2 Â 10 4 ) cells were added to each well of the 96-well tissue culture plates and incubated overnight at 37 1C in a humidified 5% CO 2 atmosphere. To one set of wells containing L929 cells, the recombinant TNF-a at 2.4 pmol l À1 and its 5-fold dilutions were added. To another set of wells, the transfected tumor cell culture supernatants were added. After 3 days of incubation of the above plates, 15 ml of dye solution were added to each well by using Cytotoxicity Assay kit purchased from Promega (Madison, WI). 39 After another 4 h incubation at 37 1C, 100 ml of solubilization/stop solution were added to each well. The plates were then read at 595 nm in a BioRad Model 3550 microplate reader.
Transfection of BL6-10 OVA tumor cells in vitro and in vivo with AdV TERT LacZ and AdV TERT Luc In an in vitro transfection assay, BL6-10 OVA tumor cells were cultured in a medium containing AdV TERT LacZ at MOI of 200 for 2 h.
38 Medium-containing viruses were then removed and replaced with the regular medium. Cells were cultured for another 24 h and then analyzed for b-gal expression as described earlier. 38 Briefly, transfected BL6-10 OVA tumor cells were fixed in PBS containing 10% formaldehyde and 25% glutaraldehyde, stained with X-gal and then counterstained with nuclear fast red (Poly Scientific, Bay Shore, NY). Positive cells had a blue color. In an in vivo transfection assay, C57BL/6 mice were subcutaneously (s.c.) inoculated with BL6-10 OVA tumor cells (0.5 Â 10 6 cells per mouse) in their right thigh. When BL6-10 OVA tumors grew to 6-8 cm in diameter, mice were intratumorally injected with AdVLuc and AdV TERT Luc (2 Â 10 9 PFU/10 ml PBS/mouse), respectively. After 2-3 days, mice were killed, and tumors and different organs were removed and the protein extracts were prepared by homogenizing tissues in luciferase buffer at 0.5 g of tissue per ml as described earlier. 40 Luciferase activities from tumors and different mouse organs were estimated by using the Luciferase kit (Promega, Madison, WI) according to the manufacturer's protocol. 33 A scintillation counter was used to measure the emitted light. The amount of luciferase present in the tumors and tissues from various organs was estimated using a standard curve.
Adenovirus-mediated TNF-a gene therapy and longterm protective immunity C57BL/6 mice (eight per group) were s.c. inoculated in their right thighs with 0.5 Â 10 6 viable BL6-10 OVA tumor cells. To assess the toxicity of mutant mTNF-a, the recombinant AdVmTNF-a, AdVTNF-a and AdVpLpA at various plaque forming units (PFUs) in a volume of 10-20 ml of PBS were i.t. injected into tumors when tumors reached B5 mm in diameter. The mouse's condition was monitored closely. The mouse mortality was then examined as described earlier. 12 To assess the therapeutic effect, the recombinant adenoviruses (Ad-V TERT mTNF-a or AdV TERT pLpA) at 2 Â 10 9 PFU in a volume of 10-20 ml of PBS were i.t. injected into tumors when tumors reached B6 mm in diameter. Tumor growth was monitored once every 3 days by measuring two perpendicular tumor diameters using a precision caliper. Animals with tumor regression were monitored for another 30 days. Animal showing growth of tumors that exceeded 1.5 cm in diameter were killed for ethical reasons according to the institutional guidelines. To assess the long-term protective immunity, the tumor-cured mice (six per group) with tumor complete regression for more than 1 month were s.c rechallenged in their left thighs with BL6-10 OVA tumor cells (0.5 Â 10 6 cells per mouse). Tumor growth or regression was monitored for another 30 days. For humanitarian reasons, all mice with tumors that achieved a size of 1.5 cm in diameter were killed.
Histology
One day subsequent to the injection of AdV TERT mTNF-a (2 Â 10 9 PFU per mouse tumor), tumor nodules were removed. Eight days after the injection of Ad-V TERT mTNF-a, the tissues at the injection sites of mice with tumor regression were also removed. The removed tumora and tissues were fixed in 10% formaldehyde and embedded in paraffin for histological analysis. Sections of 6-7 mm thickness were stained with hematoxylin-eosin according to the standard procedures.
Adoptive immunity transfer
The tumor-cured mice (10 per group) that are the mice with complete tumor regression for more than 1 month were given an i.v. booster dose of BL6-10 OVA tumor cells (0.5 Â 10 6 cells per mouse). Six days after the boost, mouse splenocytes were harvested and the red cells were lysed using 0.84% Tris-ammonium chloride. T cells were enriched by a passage through nylon columns (C&A Scientific, Mannose, VA). CD4 þ and CD8 þ T cells were then purified by negative selection using anti-CD8 and anti-CD4 magnetic beads (Dynal, Lake Success, NY) as described earlier. 35 Purified CD4 þ and CD8 þ T cells (10 Â 10 6 cells per mouse) were i.v. injected into athymic nude mice. The above mice were s.c. inoculated in their right thighs with BL6-10 OVA tumor cells (0.5 Â 10 6 cells per mouse) one day after the T-cell transfer. Tumor growth or regression was monitored for another 30 days.
Statistical analyses
Statistical analyses were performed using Prism software (GraphPad Software Inc., San Diego, CA) to form Kaplan-Meier survival chart and to perform a Log-rank test to compare mouse survival and tumor development between groups. 41 P-values less than 0.05 (Po0.05) were considered statistically significant.
Results
Mutant mTNF-a transgene expression has less in vivo toxicity We constructed adenoviral vectors AdVTNF-a and AdVmTNF-a expressing the wild-type murine TNF-a and the mutant TNF-a (mTNF-a) with mutations at D142N and A144R under control of CMV promoter. To assess the in vivo toxicity of transgene TNF-a expression, we performed intratumoral injection of AdVTNF-a and AdVmTNF-a into BL6-10 OVA tumors and mouse mortality was monitored. As shown in Exp I of Table 1 , the intratumoral injection of AdVTNF-a at doses of 1X10 8 and 5X10
8 PFU resulted in death of 2/8 (25%) and 7/8 (88%) mice due to its in vivo toxicity, whereas AdVmTNF-a expressing the mutant mTNF-a at the same doses did not cause any mouse death, indicating that the mTNF-a with mutations at D142N and A144R greatly reduces its in vivo toxicity.
Mutant mTNF-a maintains its functional effect on stimulation of T-cell proliferation but loses its cytotoxic effect AdVmTNF-a was used to transfect BL6-10 OVA tumor cells at MOI of 200. To assess the amount of mTNF-a secretion, we performed a TNF-a ELISA assay by using a TNF-a ELISA kit. We found that the mTNF-a secretion was estimated to be 2.0 ng ml À1 . The proliferative signals are commonly derived from the activation of p75 TNFR. 12, 14, 15 To assess the proliferative effect of the secreted mutant mTNF-a in transfected tumor cell culture, we performed the in vitro T-cell proliferation assay. As shown in Figure 1a , the control recombinant TNF-a stimulated CTLL-2T cell proliferation in a dosedependent manner. Both supernatants from AdVTNF-aand AdVmTNF-a-transfected tumor cells also stimulated CTLL-2T cell proliferation to a similar extent, indicating that the secreted mutant mTNF-a in AdVmTNF-atransfected tumor cell culture supernatants is functional.
The induction of cytotoxicity by TNF-a is primarily signaled through the p55 TNFR. 11, 12 To assess the cytotoxicity effect of the secreted mutant mTNF-a, we performed the in vitro cytotoxicity assay. As shown in Figure 1b , the control recombinant TNF-a as well as the supernatant containing secreted TNF-a displayed cytotoxicity to L929 cells in a dose-dependent fashion, whereas the secreted mutant mTNF-a from AdVmTNFa-transfected tumor cell culture supernatant did not show any killing activity to L929 cells, indicating that the mutant mTNF-a may lose its binding to p55 TNFR.
Transgene expression under control of hTERT promoter is restricted in tumor cells
To assess the transgene expression in tumors, we performed in vitro and in vivo transfection assays by CTLL-2 cells deprived of IL-2 for 24 h in culture were added into 96-well microtiter plates. To one set of wells containing CTLL-2 cells, the recombinant TNF-a at 2.4 pmol l -1 and its 5-fold dilutions were added. To another set of wells, the culture supernatants were added. (b) Cytotoxicity assay. L929 cells were added to each well of the 96-well tissue culture plates and incubated overnight at 37 1C. To one set of wells containing L929 cells, the recombinant TNF-a at 2.4 pmol l À1 and its 5-fold dilutions were added. To another set of wells, the transfected tumor cell culture supernatants were added. After 3 days of incubation of the above plates, 15 ml of dye solution were added to each well. After another 4 h incubation at 37 1C, 100 ml of solubilization/stop solution were added to each well. The plates were then read at 595 nm in a Bio-Rad Model 3550 microplate reader. The standard deviation of each sample was less than 3%. One representative data of three were shown. We previously demonstrated that the transgene expression under control of CMV promoter occurred in both normal and tumor cells. 25 As shown in Figure 2A , however, AdV TERT LacZ-mediated LacZ expression under the control of hTERT promoter only occurred in BL6-10 OVA tumors but not in normal fibroblast cells, indicating that the in vitro transgene expression under control of hTERT promoter is restricted in tumor cells. To assess the transgene expression in vivo, we performed a biodistribution study by intratumoral injection of AdVLuc and AdV TERT Luc. Three days after intratumoral injection of AdV, the mice were killed and different organs were removed and homogenized for the measurement of luciferase activity. As shown in Figure 2B , the majority of transgene Luc expressions even under the control of a CMV promoter by AdVLuc transfection was in tumors, spleens and livers. However, the transgene Luc expression under the control of a hTERT promoter by AdV TERT Luc transfection was exclusively limited to the tumors, confirming that the in vivo transgene expression under the control of a hTERT promoter is highly restricted in tumor cells.
Mutant mTNF-a transgene expression under the control of a hTERT promoter has much less in vivo toxicity We also constructed AdV TERT mTNF-a expressing the mutant TNF-a (mTNF-a) under the control of a human TERT promoter. The supernatants of AdV TERT mTNF-atransfected BL6-10 OVA cell culture contained a similar amount of mTNF-a (1.6 ng ml
À1
) as in supernatants of AdVmTNF-a-transfected BL6-10 OVA cells (2.0 ng ml À1 ), indicating that the hTERT promoter is as strong as the commonly used CMV promoter in driving the mTNF-a expression in tumor cells. To assess the cytotoxic sideeffect of transgene mTNF-a expression under control of hTERT promoter, we administered an intratumoral injection of AdVmTNF-a and AdV TERT mTNF-a into BL6-10 OVA tumors and mouse mortality was monitored. As shown in Exp II of Table 1 , the intratumoral injection of AdVmTNF-a expressing mTNF-a under the control of a CMV promoter at doses of 1 Â 10 9 and 5 Â 10 9 PFU resulted in mouse death in 3/8 (38%) and 8/8 (100%) mice because of its in vivo toxicity. However, AdV TERT mTNFa expressing mTNF-a under the control of a hTERT promoter at 1 Â 10 9 PFU did not cause any mouse death. At a higher dose of 5 Â 10 9 PFU, AdV TERT mTNF-amediated gene therapy only resulted in mouse death in 1/8 (13%) mice, indicating that the mutant mTNF-a Mutant mTNF-a transgene expression under the control of a hTERT promoter eradicates well-established tumors and induces long-term antitumor immunity Previous reports have shown that AdVTNF-a can inhibit tumor growth in tumor-bearing mice. 12, [23] [24] [25] To examine the therapeutic effect of AdV TERT mTNF-a in murine B16 melanoma model, we intratumorally injected into each tumor (B6 mm in diameter) with a low (2 Â 10 8 PFU per mouse tumor) and a high (2 Â 10 9 PFU per mouse tumor) dose of AdV TERT mTNF-a and AdVmTNF-a. Tumor growth or regression was monitored. When tumorbearing mice were treated with AdV TERT mTNF-a and AdVmTNF-a at low doses, we found that most tumors regressed within the first 2 days of AdV injection due to the tumor necrosis formation (Figure 3a ). However, all tumors then gradually grew up and all mice died of tumors (Figure 3b ). Both AdV TERT mTNF-a and AdVmTNF-a treatment at a low dose, though did not cure any tumor-bearing mice, significantly prolonged the tumor-bearing mouse survival (Po0.05). The treatment of AdV TERT mTNF-a at high doses cured 4/10 tumorbearing mice, and the remaining mice (six) in that mouse group had also significantly prolonged mouse survival compared with the control AdV TERT pLpA-treated mice (Po0.05), though they eventually died (Figure 3c) , indicating that the mutant mTNF-a transgene expression under control of hTERT promoter can completely eradicate some well-established tumors. We did not perform a study of AdVmTNF-a treatment at high doses as 7/8 tumor-bearing mice died within 2-4 days subsequent to the intratumoral injection of AdV. To assess the long-term immunity, we rechallenged the tumor-cured mice with BL6-10 OVA or the control BL6-10 tumor cells 1 month after tumor regression. As shown in Table 2 , no tumor growth was found in these tumor-cured mice when mice were inoculated with OVA-expressing BL6-10 OVA tumor cells, whereas all tumor-cured mice grew BL6-10 tumors without OVA expression, indicating that the tumor-cured mice develop long-term OVA-specific antitumor immunity.
The long-term antitumor immunity derived from mutant mTNF-a transgene therapy is mediated by CD8 þ CTL responses To assess the cellular mechanism responsible for the longterm immunity, we purified CD4 þ and CD8 þ T cells from the tumor-cured mouse spleens and separately transferred them into athymic nude mice. We then inoculated these nude mice with BL6-10 OVA tumor cells. As shown in Figure 4 , all nude mice with transfer of CD8 þ T cells, but not CD4 þ T cells were protected against the challenge of BL6-10 OVA tumor cells, indicating that the long-term antitumor immunity derived from AdV TERT mTNF-a gene therapy is mediated by CD8 þ T cells.
Discussion
Retrovirus and adenovirus (AdV) are commonly used for the delivery of transgenes to cells or tissues. 42 Retroviruses integrate their genome into the host DNA of dividing cells, and this provides the possibility of longterm transgene expression. However, its random integration may cause insertional mutagenesis in the host cells. Recently, it has been shown that retroviral vectors can cause leukemia formation. 43 However, the use of AdVs is relatively safe due to its low potential for insertional mutagenesis. 44 To prevent the toxicity of transgenes in normal cells, a targeted expression of desired therapeutic proteins within the tumor mass is desired. Targeted gene transfer may greatly increase the number of proteins that can be used for antitumor treatment, as many proteins that otherwise have too many undesirable adverse effects might then be used to treat tumors. Control of gene expression through tissue promoters has been widely used for targeting the transgene expression, which includes the tyrosinase gene promoter in melanomas, the carcinoembryonic antigen promoter in colorectal cancers, the E2F promoter in cancers that carry a defective retinoblastoma gene and MUC 1 promoter in breast cancers. [45] [46] [47] [48] However, most of these promoters are relatively weaker than other commonly used viral promoters such as cytomegalovirus and SV40 early promoters. Therefore, the use of these tissue-specific promoters has been hampered by the problem of low expression. In this study, we demonstrated that (i) the transgene expression under the control of a hTERT promoter is highly restricted in tumor cells and induces less cytotoxicity in mice, and (ii) the hTERT promoter is as strong as the commonly used CMV promoter in driving the mTNF-a expression of tumor cells. Interestingly, the transgene mTNF-a expression under control of hTERT promoter also completely eradicated well-established tumors (B6 mm in diameter) in 4/10 tumor-bearing mice.
The antitumor activity of TNF-a is mediated in at least three different ways. The first mechanism is mediated by its direct cytotoxicity to tumor cells by inducing apoptosis through engagement of the p55 TNF-a receptor I.
11,12
The second mechanism is through its immune activation of macrophages, natural killer and T cells 3 by its binding to the p75 TNF-a receptor II. 11, 12 The third mechanism is mediated by its effects on tumor vasculature by deactivation of aVaˆ3 integrin on angiogenic endothelial cells leading to a lack of adhesion and apoptosis, 49 promoting intravascular thrombosis and inducing ischemic necrosis 50 and, consequently, tumor regression. 11, 12 In this study, we showed that, when mice were treated at a high dose of AdV TERT mTNF-a, all tumors regressed within the first 2 days of AdV injection and some of them then gradually grew up again. Considering the early onset of the necrosis, it is unlikely to be due to the activation of T cells but rather the result of mediation through the third mechanism, in which the ischemic damage secondarily invokes an influx of polymorphonuclear and mononuclear cells.
Interestingly, we found that AdV TERT mTNF-a gene therapy not only completely eradicated well-established tumors in 4/10 tumor-bearing mice, but also induced a long-term antitumor immunity in these tumor-cured mice. We further demonstrated that the long-term antitumor immunity was mediated by OVA-specific CD8 þ T cells. It has been demonstrated that exogenous tumor antigens released from apoptotic and necrotic tumor cells can be captured by dendritic cells and presented to CD8 þ T cells through the cross-priming pathway. 34, 51, 52 Therefore, the AdV TERT mTNF-a gene therapy-induced tumor necrosis may also release OVA tumor antigen, which can be crosspresented by the mouse dendritic cells to CD8 þ T cells. In addition, the hTERT is the rate-limiting component in the telomerase complex and is most closely correlated with telomerase activity. 53 The widespread expression of telomerase in tumors indicated that peptide fragments of hTERT could serve as tumor-specific antigens and this has been confirmed by some recent reports. 54, 55 Therefore, another part of the antitumor immunity may be derived from the anti-hTERT CTL responses. Taken together, we showed that the mutant TNF-a with mutations at D142N and A144R has less in vitro cytotoxic effect, but maintains its functional effect in the stimulation of T-cell proliferation. The in vitro and in vivo transgene expressions under control of hTERT promoter are highly restricted in tumor cells. The mutant mTNF-a transgene expression under the control of a hTERT promoter further reduces its in vivo toxicity. Mutant mTNF-a transgene expression under control of hTERT promoter eradicates well-established tumors and induces CD8 þ T-cell-mediated long-term antitumor immunity. Therefore, AdV TERT mTNF-a gene therapy may be useful in the immunotherapy of cancer.
